|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Basal aromatase activity and the degree of aromatase stimulation by these factors were greater in fibroblasts derived from 'normal' breast tissue than from breast tumours.
|
10731102 |
1999 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To block the growth of breast tumors, aromatase inhibitors (AIs) are employed to bind and inhibit aromatase in order to lower the amount of estrogen produced in the body.
|
30190660 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase activity in extragonadal sites contributes to this source of estrogen and may contribute to breast tumor development and/or growth.
|
11795380 |
2001 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Chromatin immunoprecipitation identified ER genomic binding activity in estrogen-deprived cells and primary breast tumors treated with aromatase inhibitors.
|
22049316 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase is the rate-limiting enzyme in estrogen biosynthesis and its expression in breast adipose stromal cells is hypothesized to drive the growth of breast tumors and confer resistance to endocrine therapy in obese postmenopausal women.
|
30851382 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that in postmenopausal women aromatase inhibitors might be considered as an adjuvant approach to the treatment of hormone-dependent breast tumors that overexpress aromatase.
|
12160997 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The purpose of the present study was to study the aromatase mRNA expression as well as promoter usage (I.4, I.3, PII and I.7) in axillary adipose tissue (AA), mammary adipose tissue (MA), breast tumor tissue (BT) and adjacent normal breast tissue (NB), and to study the relationship between aromatase mRNA expression and tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and cyclooxygenase (COX)-2 mRNA expression.
|
16287071 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
|
24923427 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study was undertaken to conduct a comprehensive investigation of the role of DNA damage repair (DDR) defects in poor outcome ER<sup>+</sup> disease.<b>Experimental Design:</b> Expression and mutational status of DDR genes in ER<sup>+</sup> breast tumors were correlated with proliferative response in neoadjuvant aromatase inhibitor therapy trials (discovery dataset), with outcomes in METABRIC, TCGA, and Loi datasets (validation datasets), and in patient-derived xenografts.
|
29793947 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Supporting data for an etiological role of aromatase in breast tumor biology are several-fold.
|
10731105 |
1999 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Transcriptional regulation of CYP19 is complex in breast tissues, in which exon switching in the usage of alternative first exons occurs from predominantly EI.4 in breast tissue from cancer-free women to predominantly EI.3 and PII in breast tumors and quadrants with or without tumor.
|
10690899 |
2000 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The aromatase enzyme, which converts androstenedione to oestrone, regulates the availability of oestrogen to support the growth of hormone-dependent breast tumours.
|
15341993 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Several recent studies demonstrated activity of aromatase, an enzyme that plays a critical role in estrogen synthesis in breast tumors.
|
18079323 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
|
25023195 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Agents that inhibit Cox-2 or block the biological effects of PGE2 may be useful in significantly limiting aromatase activity and proliferation of human breast tumor cells regardless of the presence of Cox-2.
|
16997132 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we comparatively analyzed for the first time aromatase, estrogen 4-hydroxylase (CYP1B1) and fatty acid synthase immunohistochemical expression in breast tumors obtained from 12 BRCA1 mutations carriers and 22 non-carriers.
|
19083124 |
2009 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors.
|
30513833 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As tamoxifen via GPER induced aromatase expression also in CAFs, this pathway may be involved in promoting aggressive behavior of breast tumors in response to tamoxifen treatment.
|
24928526 |
2014 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar magnitude suggestive association, although nonstatistically significant, was found between Val(80) polymorphism and estrogen receptor-negative status of the breast tumors.
|
19366906 |
2009 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study sought to provide more direct evidence of the predominant role for stromal cell aromatase in breast tumor tissue.
|
8989259 |
1997 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue.
|
11973645 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, RT-PCR analyses of RNA isolated from eight pairs of breast tumor and neighboring normal tissue specimens were performed to evaluate the exon I usage and the distribution of I.3A- and I.3B-containing aromatase RNA messages in breast tumor and neighboring normal tissues.
|
9010331 |
1996 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
|
12114443 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We determined the effects of the combination of RT and letrozole in the aromatase-expressing breast tumour cell line MCF-7CA, stably transfected with the CYP19 gene.
|
15642164 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because the expression of aromatase in breast cancer tissues is driven by unique promoters I.3 and II, a more complete understanding of the regulatory mechanism of aromatase expression through promoters I.3/II in breast tumors should be valuable in developing targeted therapies, which selectively suppress estrogen production in breast tumor tissue.
|
18519709 |
2008 |